Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics PLC grows in Europe and targets US

Revenue in the six months to December 31 rose 12% to £31.5mln
Allergy Therapeutics PLC grows in Europe and targets US
Allergy Therapeutics hopes to expand vaccine business in the US

Allergy Therapeutics PLC (LON:AGY) reported higher revenues and said it had relaunched plans to enter the US market in 2019.

The allergy vaccine specialist said revenue in the six months to December 31 rose 12% to £31.5mln as its share of all major markets increased.

It started a US phase II study for its GrassMatampl product in December and said it was on track for data read-out in the second half of this year.

The group is also expecting the results of its PQ Birch204 Phase II study, for which patient enrolment is complete, in the second half.

It has restarted clinical development plans, aiming to enter the US market following Food & Drug Administration approval in 2019, thereby becoming the first company to launch a subcutaneous vaccine in the seasonal segment of the US allergic rhinitis market.

Chief executive Manuel Llobet said the company's US commercialisation strategy was where significant growth potential lies and its strengthened balance sheet left it well-placed to build a strong allergy business.

"The first half of this year has seen continued momentum with our product sales continuing to outperform the market with further market share gains across Europe," he said.

"Our business is gaining significant scale and momentum in Europe through both organic and acquisitive growth.

"We expect this to continue as we further invest in our commercial infrastructure and prepare to take our products over to the US."

Phil-Waller.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
Lab.jpg
April 05 2017
The share placing follows a period of expansion that has seen it make two major acquisition

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use